Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating the effects of AZD6234 as an additional treatment alongside incretin-based therapies in adults who are overweight or have obesity with at least one weight-related health condition, with or without Type 2 Diabetes Mellitus. This Phase III global study will compare how well AZD6234 works against a placebo by measuring changes in body weight over 68 weeks. Participants will be randomly assigned to receive either AZD6234 or a matching placebo, both given as weekly injections under the skin. These treatments will be added to their stable dose of existing incretin-based medications. The study is designed to monitor participants for 68 weeks of treatment to assess the impact on body weight and related health measures. During the study, participants will undergo regular assessments including body weight measurements, waist circumference, blood pressure, blood tests for triglycerides and HbA1c, and evaluation of weight loss milestones. Safety and effectiveness will be closely monitored throughout the treatment period, which lasts about 68 weeks. The study aims to provide detailed information on how AZD6234 affects weight and metabolic health in this population.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Chronic low back pain is common in older adults and is linked to problems with balance, higher chances of falling, frailty, depression, and reduced physical ability. Researchers are studying how different ways of focusing attention during virtual reality-based exercise might affect these issues. This trial compares the effects of focusing attention externally versus internally during a core stabilization exercise program in older adults with chronic low back pain. Participants will be randomly assigned to two groups one receiving verbal and visual cues to focus on movement effects on the environment external focus, and the other focusing on body movements and muscle control internal focus. Both groups will perform the same virtual reality-assisted core stabilization exercises three times a week for six weeks, with sessions lasting 45 to 60 minutes under physiotherapist supervision in a safe clinical setting. Participants will be assessed before and after the six-week program using measures such as frailty level, balance and fall risk, lower limb strength, sarcopenia risk, and depression symptoms. Tests include the Frailty Assessment Scale, Biodex Balance System, Five Times Sit-to-Stand Test, SARC-T questionnaire, and Beck Depression Inventory. Researchers aim to find out if the different focus strategies lead to different physical, functional, and psychological outcomes in these older adults.
Actively Recruiting
Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.
Actively Recruiting
Researchers are evaluating the impact of nurse-led self-acupressure on blood pressure, stress, and well-being in adults with primary hypertension. This randomized controlled trial compares real acupressure, sham acupressure, and usual care to understand how these approaches affect individuals with stage 1 or 2 primary hypertension who are already taking antihypertensive medication. Participants are assigned to one of three groups real acupressure applied to specific points HT7, LI4, PC6, EX3 for 15 seconds per point, three days a week over two weeks sham acupressure at non-acupoint sites near these points with the same schedule or usual care which includes prescribed medication and regular nursing follow-up without acupressure. Each acupressure session lasts about one minute. During the study, participants will be monitored for changes in blood pressure, perceived stress, and mental well-being from the start to the end of the two-week period. Nurses administer the acupressure treatments and collect data to assess the effects. The primary outcome is the change in blood pressure, while secondary outcomes include changes in stress and well-being levels. The total participation lasts approximately two weeks.
Actively Recruiting
Healthy Volunteer
Osteoporosis is a progressive disease that leads to reduced bone mass, weaker bone structure, and increased risk of fractures. Postmenopausal women are especially at risk, with over 80% affected after age 50 and nearly all individuals over 75 showing signs. This study aims to explore how virtual reality applications might improve balance, quality of life, and reduce fall risk in postmenopausal women with osteoporosis, comparing these effects to a control group receiving traditional treatment. Participants will be randomly assigned to one of two groups. The control group will receive traditional treatment including posture, strengthening, and balance exercises patient education to prevent falls and fractures aerobic exercises and pain management strategies. The virtual reality group will engage with video-based games and videos designed as exergames to encourage physical activity and balance training. The study will carefully monitor for any adverse effects from the virtual reality program and adjust it if necessary. During the 6-week study, participants will be assessed for balance, cognitive state, and risk of falling. Quality of life will also be measured as a secondary outcome. Assessments will involve physical evaluations and cognitive tests to track progress. Participants must be postmenopausal women aged 50 to 75 with osteoporosis confirmed by bone density testing, and able to walk independently. The study aims to provide new insights into the use of virtual reality as a therapeutic tool for osteoporosis-related challenges.